NCT04074161 - Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Biotech Hunter

Enrollment

338

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

March 27, 2021

Study Completion Date

May 11, 2021

Conditions

OverweightObesity

Interventions

DRUG

Semaglutide

Dose gradually increased to 2.4 mg administered once weekly for 68 weeks

DRUG

Placebo (semaglutide)

Administered once weekly for 68 weeks

DRUG

Liraglutide

Dose gradually increased to 3.0 mg administered once daily for 68 weeks

DRUG

Placebo (liraglutide)

Administered once daily for 68 weeks

Trial Locations (19)

12203

Novo Nordisk Investigational Site, Albany

22206

Novo Nordisk Investigational Site, Arlington

28401

Novo Nordisk Investigational Site, Wilmington

29425

Novo Nordisk Investigational Site, Charleston

32205

Novo Nordisk Investigational Site, Jacksonville

33324

Novo Nordisk Investigational Site, Plantation

35294

Novo Nordisk Investigational Site, Birmingham

46260

Novo Nordisk Investigational Site, Indianapolis

70808

Novo Nordisk Investigational Site, Baton Rouge

75032

Novo Nordisk Investigational Site, Rockwall

75226

Novo Nordisk Investigational Site, Dallas

75230

Novo Nordisk Investigational Site, Dallas

92648

Novo Nordisk Investigational Site, Huntington Beach

92835

Novo Nordisk Investigational Site, Fullerton

96814

Novo Nordisk Investigational Site, Honolulu

98502

Novo Nordisk Investigational Site, Olympia

60201-2477

Novo Nordisk Investigational Site, Evanston

19104-3317

Novo Nordisk Investigational Site, Philadelphia

22601-3834

Novo Nordisk Investigational Site, Winchester